GlassScriptPhysician profile
Shubha P Bhat
NPI 1518170380
$2,297.23
in general payments reported to CMS, 2019-2025
18 companies · $545 in 2025
The $545 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $95.44 · 2023: $53.73 · 2024: $1,603 · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $1,200 · Food and Beverage: $1,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $1,200.00 |
| Food and Beverage | $1,001.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $1,200.00 | 2024 | Monoferric |
| Novo Nordisk INC | $218.76 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $133.95 | 2022-2025 | Zepbound, Jardiance, Mounjaro |
| Exact Sciences Corporation | $110.93 | 2024-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $100.91 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Medtronic, INC. | $83.73 | 2022 | |
| Pfizer INC. | $66.46 | 2023-2025 | |
| Abbvie INC. | $58.45 | 2024-2025 | |
| Glaxosmithkline, LLC. | $48.94 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.46 | 2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $37.89 | 2025 | |
| Astellas Pharma US INC | $34.86 | 2025 | Veozah |
| Amgen INC. | $32.14 | 2025 | Repatha, Otezla |
| Janssen Biotech, INC. | $30.04 | 2025 | Tremfya |
| Globus Medical, INC. | $28.57 | 2025 | Senza |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $25.07 | 2025 | Freestyle Libre 3 |
| Dynavax Technologies Corporation | $21.02 | 2025 | Heplisav-B |
| Dexcom, INC. | $17.05 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shubha Bhat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.